AstraZeneca (AZN) Receives Market Perform Rating from Leerink Swann
AstraZeneca (NYSE:AZN)‘s stock had its “market perform” rating reaffirmed by investment analysts at Leerink Swann in a research report issued on Thursday. They presently have a $36.00 price objective on the stock, up from their previous price objective of $33.00. Leerink Swann’s price target would indicate a potential upside of 2.65% from the company’s previous close.
Several other equities research analysts also recently issued reports on the company. JPMorgan Chase & Co. upgraded AstraZeneca from a “neutral” rating to an “overweight” rating in a report on Friday, December 29th. Sanford C. Bernstein upgraded AstraZeneca from a “market perform” rating to an “outperform” rating and boosted their price objective for the company from $30.00 to $39.00 in a report on Friday, September 22nd. Citigroup upgraded AstraZeneca to a “buy” rating in a report on Wednesday, October 18th. BMO Capital Markets set a $38.00 price objective on AstraZeneca and gave the company a “buy” rating in a report on Wednesday, November 15th. Finally, Zacks Investment Research downgraded AstraZeneca from a “hold” rating to a “sell” rating in a report on Wednesday, January 3rd. Three analysts have rated the stock with a sell rating, eight have issued a hold rating and thirteen have given a buy rating to the company’s stock. AstraZeneca has a consensus rating of “Hold” and an average target price of $34.48.
AstraZeneca (NYSE:AZN) traded down $0.01 during mid-day trading on Thursday, hitting $35.07. The company had a trading volume of 3,102,454 shares, compared to its average volume of 3,040,000. The company has a debt-to-equity ratio of 1.09, a current ratio of 0.94 and a quick ratio of 0.72. The stock has a market cap of $87,120.00, a P/E ratio of 25.05, a PEG ratio of 3.42 and a beta of 0.76. AstraZeneca has a 52-week low of $26.51 and a 52-week high of $35.92.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. First Bank & Trust increased its holdings in AstraZeneca by 19.3% during the 4th quarter. First Bank & Trust now owns 55,597 shares of the company’s stock worth $1,929,000 after purchasing an additional 9,004 shares during the period. Bank of Montreal Can increased its holdings in AstraZeneca by 243.4% during the 4th quarter. Bank of Montreal Can now owns 415,126 shares of the company’s stock worth $14,404,000 after purchasing an additional 294,246 shares during the period. Clean Yield Group purchased a new stake in AstraZeneca during the 4th quarter worth about $205,000. Private Trust Co. NA purchased a new stake in AstraZeneca during the 4th quarter worth about $310,000. Finally, BLB&B Advisors LLC increased its holdings in AstraZeneca by 133.8% during the 4th quarter. BLB&B Advisors LLC now owns 54,849 shares of the company’s stock worth $1,903,000 after purchasing an additional 31,388 shares during the period. Institutional investors own 14.75% of the company’s stock.
AstraZeneca Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.